论文部分内容阅读
目的探讨替米沙坦联合百令胶囊治疗早期糖尿病肾病(DN)的临床疗效。方法将124例DN早期患者随机分为两组:对照组62例和治疗组62例,对照组接受饮食控制和胰岛素注射等降糖治疗的基础上给予口服替米沙坦片80 mg/次,1次/d;治疗组则在对照组的基础上加服百令胶囊1.0 g/次,3次/d。比较两组患者治疗前后尿白蛋白排泄率(UAER)的定量变化。结果两组用药后UAER均明显降低,以治疗组降低更明显,差异有统计学意义(P<0.05)。结论替米沙坦联合百令胶囊治疗早期DN疗效确切、安全,无明显不良反应。
Objective To investigate the clinical efficacy of telmisartan combined with Bailing capsule in the treatment of early diabetic nephropathy (DN). Methods One hundred and twenty-four patients with early DN were randomly divided into two groups: control group (62 cases) and treatment group (62 cases). The control group received oral administration of telmisartan 80 mg once daily on the basis of diet control and insulin injection. 1 times / d; treatment group was added on the basis of the control group Bailing capsule 1.0 g / time, 3 times / d. The changes of urinary albumin excretion (UAER) before and after treatment were compared between the two groups. Results The UAER of both groups were significantly decreased after treatment, and the reduction was more obvious in the treatment group with statistical significance (P <0.05). Conclusion Telmisartan combined with Bailing capsule treatment of early DN exact, safe, no significant adverse reactions.